Page last updated: 2024-12-06

ecabet

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ecabet: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65781
CHEMBL ID2104585
CHEBI ID135593
SCHEMBL ID373030
MeSH IDM0170985

Synonyms (32)

Synonym
NCGC00181160-01
13-isopropyl-12-sulfopodocarpa-8,11,13-trien-15-oic acid
ecabetum [inn-latin]
ecabet [inn]
ecabet
CHEBI:135593
DB05265
(1r,4as,10ar)-1,4a-dimethyl-7-propan-2-yl-6-sulfo-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid
33159-27-2
D07885
ecabet (inn)
unii-2k02669kwp
2k02669kwp ,
ecabetum
tox21_112763
dtxsid7046881 ,
cas-33159-27-2
dtxcid5026881
AKOS015917316
CHEMBL2104585
ecabet [mi]
ecabet [who-dd]
SCHEMBL373030
(1r,4as,10ar)-1,4a-dimethyl-7-(propan-2-yl)-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid
(4beta)-12-sulfoabieta-8,11,13-trien-18-oic acid
(1r,4as,10ar)-7-isopropyl-1,4a-dimethyl-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid
BCP12970
Q20817236
D81888
AS-55875
CS-0009589
HY-B0691

Research Excerpts

Overview

Ecabet sodium (ENa) is a drug that repairs epithelial cells in the digestive tract via selective adhesion to damaged tissue. Ecabet is a novel anti-ulcer agent that acts directly on the gastric mucosa, has bactericidal activity, and inhibits adhesion of Helicobacter pylori.

ExcerptReferenceRelevance
"Ecabet sodium (ES) is a new non-systemic anti-ulcer agent belonging to the category of gastroprotective agents. "( The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.
Ahn, JY; Chang, SK; Choi, CH; Han, SB; Kim, JW; Lee, JW; Park, SJ, 2015
)
2.11
"Ecabet sodium (ENa) is a drug that repairs epithelial cells in the digestive tract via selective adhesion to damaged tissue. "( Effects of ecabet sodium on acute mixed reflux esophagitis in rats.
Kashiwagi, H; Omura, N; Tsuboi, K; Yanaga, K; Yano, F, 2009
)
2.19
"Ecabet sodium (ES) is a widely employed mucoprotective agent, for the treatment of gastric ulcers. "( Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)--induced ulcers in early gastric cancer: prospective randomized study.
Asakuma, Y; Ichikawa, T; Kawasaki, M; Kitai, S; Kudo, M; Matsui, S; Okada, M; Umehara, Y,
)
1.91
"Ecabet sodium (ES) is a gastric mucosal protective and ulcer-healing agent. "( Ecabet sodium promotes the healing of trinitrobenzene-sulfonic-acid-induced ulceration by enhanced restitution of intestinal epithelial cells.
Adachi, S; Handa, O; Ichikawa, H; Kokura, S; Mizushima, K; Naito, Y; Okuda, T; Takagi, T; Uchiyama, K; Yoshikawa, T, 2010
)
3.25
"Ecabet is a novel anti-ulcer agent that acts directly on the gastric mucosa, has bactericidal activity, and inhibits adhesion of Helicobacter pylori to the gastric mucosa."( Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective, controlled study versus ranitidine.
Higuchi, K; Hosaka, Y; Imaizumi, H; Kida, M; Koizumi, W; Koshida, Y; Mitomi, H; Nagaba, S; Ohida, M; Saigenji, K; Sasaki, T; Tanabe, S,
)
1.1

Effects

Ecabet has a mucosal protection and antiEcabet sodium has an anti-H.

Ecabet has a mucosal protection and antiEcabet sodium has an anti-H. . Ecabet Sodium has preventive effects on the ability of H. to survive.

ExcerptReferenceRelevance
"Ecabet has a mucosal protection and anti"( Preparation, Characterization, and
Cho, KH; Jang, DJ; Kim, DH; Kim, JY; Maeng, HJ; Min, KA, 2019
)
1.96
"Ecabet sodium has an anti-H. "( Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T, 2011
)
2.14
"Ecabet has a mucosal protection and anti"( Preparation, Characterization, and
Cho, KH; Jang, DJ; Kim, DH; Kim, JY; Maeng, HJ; Min, KA, 2019
)
1.96
"Ecabet sodium has an anti-H. "( Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T, 2011
)
2.14
"Ecabet sodium has preventive effects on the ability of H."( Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8.
Fukuda, S; Liu, Q; Munakata, A; Nakaji, S; Shimoyama, T; Sugawara, K, 2001
)
2.47

Actions

ExcerptReferenceRelevance
"The ecabet-induced increase in membrane fluidity may be involved in part in the liberation of AA from the gastric mucosal cells."( Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent.
Kinoshita, M; Tamaki, H, 1997
)
1

Treatment

ExcerptReferenceRelevance
"The ecabet-pretreated cells exhibited the responsiveness to H."( Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells.
Kawahara, T; Kishi, K; Kusumoto, K; Kuwano, Y; Morita, K; Rokutan, K; Teshima-Kondo, S, 2005
)
2.25

Toxicity

ExcerptReferenceRelevance
" There was no clinically significant adverse event in both groups."( Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial.
Choi, SR; Hahm, KB; Kim, JJ; Kim, N; Kim, SK; Lee, DH; Lee, EH; Lee, JH; Lee, ST; Park, JJ; Rhee, JC, 2006
)
0.64
" Safety and tolerability were assessed by adverse events, physical examination and serum biochemistry."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.65
"In both the single- and multiple-dose studies, no severe adverse events were observed in any of the volunteers."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.65
"Bismuthyl ecabet was shown to be safe and well tolerated in healthy Chinese subjects."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
1.05

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Intravenous dosing of TA-2711 (10-100 mg/kg) never produced such effects on ethanol-induced lesions and pepsin activity as observed by oral administration."( Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats.
Magaribuchi, T; Onoda, Y; Tamaki, H, 1989
)
0.28
" These results suggest that oral dosing of ecabet reduces the peptic activity of gastric juice by precipitating pepsin, which is facilitated by an unknown component(s) of gastric juice, and that the inactivation of pepsinogen may also contribute to the anti-peptic activity of ecabet."( Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein.
Ito, Y; Nakamura, S; Onoda, Y; Sugawara, Y; Takaiti, O, 1993
)
0.83
" There were four experimental groups: Group A (sham-operated rats), Group B (AMRE rats), Group C (AMRE rats dosed with ENa at 10 mg/kg), and Group D (AMRE rats dosed with ENa at 30 mg/kg)."( Effects of ecabet sodium on acute mixed reflux esophagitis in rats.
Kashiwagi, H; Omura, N; Tsuboi, K; Yanaga, K; Yano, F, 2009
)
0.74
" The oral dosing regimen selected for subsequent phase II/III clinical trials was 800 mg twice daily."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.65
" In the in vivo efficacy study, gastro-retentive dosage forms of ECS did not influence the mucoprotective effect in the immediate irritation model but enhanced the effect in the delayed irritation model compared with ECS suspension."( Efficacy of gastro-retentive forms of ecabet sodium in the treatment of gastric ulcer in rats.
Bae, HJ; Choi, J; Kim, JY; Kim, SW; Lee, SH; Lim, JR; Park, ES, 2014
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.13170.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.16)18.7374
1990's28 (32.56)18.2507
2000's41 (47.67)29.6817
2010's15 (17.44)24.3611
2020's1 (1.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.42 (24.57)
Research Supply Index4.73 (2.92)
Research Growth Index6.37 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (24.44%)5.53%
Reviews8 (8.89%)6.00%
Case Studies5 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other55 (61.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial [NCT01308177]Phase 490 participants (Anticipated)Interventional2011-03-31Enrolling by invitation
Randomized Controlled Trial to Evaluate the Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease [NCT01039558]30 participants (Anticipated)Interventional2009-12-31Completed
[NCT00667004]Phase 2183 participants (Actual)Interventional2008-03-22Completed
Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome [NCT00198536]Phase 2/Phase 3159 participants (Actual)Interventional2005-04-30Completed
Efficacy and Safety of Ecabet Ophthalmic Solution for the Treatment of Dry Eye Syndrome [NCT00370747]Phase 2162 participants Interventional2006-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00667004 (1) [back to overview]Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test

Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test

The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured. (NCT00667004)
Timeframe: 43 days

,
Interventionmm (Mean)
AnesthetizedUnanesthetized
Ecabet Ophthalmic Solution3.022.35
Vehicle2.151.35

[back to top]